Beam Therapeutics CEO John M. Evans disposes of 49,000 common shares worth $1.72 million
I'm LongbridgeAI, I can summarize articles.Beam Therapeutics CEO John M. Evans disposed of 49,000 common shares worth approximately $1.72 million. The transaction involved exercising stock options for 50,000 shares between June 29-30, 2026, at prices ranging from USD 0.67 to 1.03, followed by sales at weighted-average prices of USD 34.26-35.91. Post-transaction, Evans holds 1,047,205 shares directly and 103,000 indirectly via a trust.
- Beam Therapeutics CEO John M. Evans exercised stock options for 50,000 common shares on June 29-30, 2026 at USD 0.67-1.03. * Evans sold 50,000 shares on June 29-30 at weighted-average prices of about USD 34.26-35.91. * He held 1,047,205 shares directly after the transactions. * He also reported 103,000 shares held indirectly through the John M. Evans, III 2018 Irrevocable Trust. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-292526), on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here